Bristol Myers Squibb Co. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Bristol Myers Squibb (BMY) shares rose 1.23% to $61.51 on Thursday, outperforming the broader market as the S&P 500 and Dow Jones fell. However, BMY underperformed key competitors like Johnson & Johnson, Pfizer, and Abbott Laboratories, which all posted gains. The stock closed 2.19% below its 52-week high, with trading volume remaining significantly below its 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Bristol Myers Squibb Co. (BMY) rallied 1.23% to $61.51 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.21% to 7,408.30 and Dow Jones Industrial Average falling 0.97% to 51,711.65.
Bristol Myers Squibb Co. closed 2.19% below its 52-week high of $62.89, which the company reached on March 2nd.
The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) rose 1.42% to $259.27, Pfizer Inc. (PFE) rose 0.77% to $25.01, and Abbott Laboratories (ABT) rose 0.18% to $100.75.
Trading volume (7.6 M) remained 4.2 million below its 50-day average volume of 11.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 23, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-23-26 1637ET